Melatonin and Macular Degeneration: What the Research Says (2026 Update)
Most people know melatonin as a sleep supplement. Fewer know that melatonin is one of the most potent antioxidants produced by the human body, and that its presence in retinal tissue may play a meaningful role in protecting against age-related macular degeneration.
This article examines what the published research says about the relationship between melatonin and AMD — including what we know with confidence, what's still emerging, and why MacuRest was formulated with melatonin as a core component.
What is melatonin, exactly?
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized primarily by the pineal gland in response to darkness. Its most recognized function is regulating the sleep-wake cycle. But melatonin has a parallel role that receives far less attention: it's a free-radical scavenger with potent antioxidant properties that neutralizes reactive oxygen species contributing to cellular aging and disease.
Of particular relevance to AMD: the retina is one of the highest oxygen-consuming tissues in the body and one of the most vulnerable to oxidative stress. It has among the highest concentrations of melatonin receptors of any tissue in the body.
Melatonin in the retina: what it does
The retina doesn't just receive melatonin from the pineal gland — it also synthesizes melatonin locally, particularly in the photoreceptors. Retinal melatonin production follows a circadian rhythm, peaking at night. Melatonin in the retina appears to serve several functions:
Antioxidant protection of the RPE
The retinal pigment epithelium (RPE) is the primary site of damage in AMD. Melatonin's antioxidant activity in the RPE has been demonstrated in cell studies and animal models. It appears to reduce lipid peroxidation in RPE cells and protect mitochondrial function — both important mechanisms in AMD pathology.
Regulation of the RPE's circadian renewal cycle
The RPE's critical function of clearing shed photoreceptor outer segments has a strong circadian pattern, guided in part by melatonin signaling. Disruption of this cycle — by shift work, blue light exposure, or declining melatonin production with age — has been proposed as a contributing factor to AMD.
Clinical evidence: what studies say
Observational studies
Multiple observational studies have found that AMD patients have lower circulating melatonin levels than age-matched controls without AMD. A 2014 study in Molecular Vision found that melatonin metabolite levels were significantly lower in patients with AMD, suggesting either reduced production or increased consumption by oxidative stress in the diseased retina.
Animal studies
A 2021 study in Antioxidants found that melatonin supplementation significantly reduced photoreceptor loss and RPE damage in a light-induced retinal degeneration model. Research in Free Radical Biology and Medicine found melatonin suppressed oxidative stress markers in RPE cells exposed to damage that characterizes AMD pathology.
Human clinical trials
The most-cited human intervention study is Feher et al. (2005), published in the Annals of the New York Academy of Sciences. In this study, 100 AMD patients received 3mg of melatonin nightly for 6 months. The majority of patients maintained visual acuity, and in those with pathological macular changes, the damage appeared to be reduced compared to what would be expected without treatment.
The Feher study is small and lacks the rigor of the AREDS 2 RCT. However, it represents the kind of preliminary human signal that justifies further investigation — and that makes melatonin supplementation a reasonable addition to an AREDS 2 regimen.
Why melatonin declines with age — and why that matters for AMD
Melatonin production from the pineal gland decreases significantly with age, accelerating after 60 — precisely the age range in which AMD prevalence increases dramatically. AMD risk increases after 60. Melatonin production decreases after 60. The retina is highly dependent on melatonin for antioxidant protection and circadian renewal. Whether the melatonin decline causes or accelerates AMD is not yet definitively established, but the convergence of timing and mechanism makes the relationship worth taking seriously.
Why MacuRest includes melatonin
MacuRest addresses two things that standard AREDS 2 supplements leave on the table:
The overnight repair window: Taking an AREDS 2-based supplement in the evening means the antioxidant and carotenoid nutrients are present during the hours your RPE is most active — not metabolized and cleared before nightfall.
The melatonin decline: For patients over 60, natural melatonin production is reduced. Supplementing with 5mg of melatonin nightly restores a physiologically meaningful level of retinal antioxidant protection and supports the circadian signaling that governs RPE renewal.
Melatonin safety in AMD patients
At doses used in supplementation (3–10mg), melatonin has a well-established safety record and is available over the counter in the United States. It is not habit-forming. Known side effects are generally mild and include morning grogginess (typically from doses above 5mg or taking it too early), vivid dreams, and occasional headache. There are no documented contraindications with AREDS 2 nutrients.
Frequently asked questions
Does melatonin help macular degeneration?
Emerging research suggests melatonin may protect against AMD progression through antioxidant mechanisms and support of the retina's circadian repair cycle. Evidence is promising but not yet at the level of AREDS 2 completed trials.
How much melatonin should AMD patients take?
MacuRest contains 5mg per serving. The most-cited human study used 3mg. Most AMD research has used doses in the 3–10mg range. Consult your ophthalmologist for a personalized recommendation.
Can melatonin slow macular degeneration?
Early studies suggest it may help slow progression in some patients. Melatonin should be considered a supportive supplement alongside AREDS 2 — not a replacement.
Is melatonin safe to take with AREDS 2?
Yes. Melatonin and AREDS 2 nutrients have no known adverse interactions. MacuRest combines both in a single evening-use formula.
References
1. Feher, J., et al. (2005). Melatonin protects and rescues retinal pigment epithelial cells from oxidative stress. Annals of the New York Academy of Sciences.
2. Yi, C., et al. (2005). Effects of melatonin in age-related macular degeneration. Annals of the New York Academy of Sciences.
3. Rosen, R., et al. (2012). Melatonin in the retina. Advances in Experimental Medicine and Biology.
4. Mehrzadi, S., et al. (2020). SIRT1 activation by melatonin: a novel pathway in retinal protection. Antioxidants.
This article is for educational purposes and does not constitute medical advice. Patients with AMD or other retinal conditions should work with their ophthalmologist before modifying their supplement regimen.